舒肝解郁胶囊联合莫沙必利治疗功能性消化不良疗效评价

目的观察抗抑郁中药联合促动力剂治疗功能性消化不良（FD）的疗效及安全性。方法将符合FD罗马Ⅲ诊断标准的86例患者随机分为两组,治疗组46例应用舒肝解郁胶囊2粒Bid、莫沙必利5mgTid。对照组40例单给莫沙必利5mgTid。两组疗程均为6周。采用临床症状评分、HAMD、HAMA评分评定疗效。结果治疗6周后,治疗组临床症状评分、HAMA、HAMD评分均较治疗前明显降低（P〈0.01）,治疗组临床治愈率为63.04%、总显效率为84.78%,均显著高于对照组的20.00%、50.00%,差异有统计学意义（P﹤0.01）。结论舒肝解郁胶囊联合莫沙必利治疗功能性消化不良,疗效肯定,且患者依从性好,不良反应少且轻微。

The efficacy evaluation of Shugan Jieyu capsule and mosapride in treatment of functional dyspepsia

Objective To observe the therapeutic effect and security of the anti-depressant traditional Chinese drug combined prokinetic agent on functional dyspepsia (FD). Methods Eighty-six patients who consistent with FD Rome Ⅲ diagnostic criteria were randomly divided into 2 groups, 46 cases of treatment group were given Shugan Jieyu capsules two tablets Bid and mosapride 5 mg Tid for six weeks. Meanwhile, the control group of 40 cases was treated with mosapride 5 mg Tid only. Clinical symptom scores, HAMD and HAMA score assessment were utilized to assess the efficacy. Results The clinical symptom score, HAMA and HAMD score of treatment group were lower than before (P < 0.01) after 6 weeks’ treatment. The clinical cure rate was 63.04% and the total markedly effective rate was 84.78% of treatment group, which were significantly higher than 20.00% and 50.00% of control group, the difference was significant (P < 0.01). Conclusion There is a positive therapeutic effect of Shugan Jieyu capsule combined with mosapride on functional dyspepsia, and good patient compliance. Adverse reactions are few and minor as well.